Unknown

Dataset Information

0

Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.


ABSTRACT: SLC22A18, solute carrier family 22, member 18, has been proposed to function as a tumor suppressor based on its chromosomal location at 11p15.5, mutations and aberrant splicing in several types of cancer and down-regulation in glioblastoma. In this study, we sought to demonstrate the significance of SLC22A18 as a tumor suppressor in colorectal cancer (CRC) and provide mechanistic bases for its function. We first showed that the expression of SLC22A18 is significantly down-regulated in tumor tissues using matched normal-tumor samples from CRC patients. This finding was also supported by publically accessible data from The Cancer Genome Atlas (TCGA). Functionally, SLC22A18 inhibits colony formation and induces of G2/M arrest consistent with being a tumor suppressor. Interestingly, suppression of KRAS by RNA interference promotes SLC22A18 expression, and expression of SLC22A18 in turn inhibits KRAS(G12D)-mediated anchorage independent growth of NIH3T3 cells indicating a mutual negative interaction. Finally, we evaluated diagnostic and prognostic values of SLC22A18 using clinical and gene expression data from TCGA which revealed a significantly worse long-term prognosis for patients with low level SLC22A18 expression. In sum, we established SLC22A18 as a tumor suppressor in colon epithelial cells and propose that SLC22A18 is potentially a marker of diagnostic and prognostic values.

SUBMITTER: Jung Y 

PROVIDER: S-EPMC4694837 | biostudies-other | 2015 Sep

REPOSITORIES: biostudies-other

altmetric image

Publications

Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.

Jung Yeonjoo Y   Jun Yukyung Y   Lee Hee-Young HY   Kim Suyeon S   Jung Yeonhwa Y   Keum Juhee J   Lee Yeo Song YS   Cho Yong Beom YB   Lee Sanghyuk S   Kim Jaesang J  

Oncotarget 20150901 28


SLC22A18, solute carrier family 22, member 18, has been proposed to function as a tumor suppressor based on its chromosomal location at 11p15.5, mutations and aberrant splicing in several types of cancer and down-regulation in glioblastoma. In this study, we sought to demonstrate the significance of SLC22A18 as a tumor suppressor in colorectal cancer (CRC) and provide mechanistic bases for its function. We first showed that the expression of SLC22A18 is significantly down-regulated in tumor tiss  ...[more]

Similar Datasets

| S-EPMC8969217 | biostudies-literature
| S-EPMC4598814 | biostudies-literature
| S-EPMC4669959 | biostudies-literature
| S-EPMC7352651 | biostudies-literature
| S-EPMC9519006 | biostudies-literature
| S-EPMC8803425 | biostudies-literature
| S-EPMC4480701 | biostudies-literature
| S-EPMC6441464 | biostudies-literature
2015-09-02 | GSE64114 | GEO
2015-09-02 | GSE64112 | GEO